White M, Pelletier G B, Tan A, Jesina C, Carrier M
Department of Medicine (Cardiology), and Surgery, Montreal Heart Institute, Quebec, Canada.
J Heart Lung Transplant. 1997 Aug;16(8):787-94.
Cyclosporine is a potent immunosuppressive agent that is, however, associated with systemic hypertension and renal dysfunction. The purpose of this investigation was to study the pharmacokinetic and long-term renal and hypertensive effects of Sandimmune (Sandoz) versus the new Neoral (Novartis) formulation of cyclosporine in heart transplant recipients.
Twenty heart transplant recipients with stable conditions and aged 54 +/- 9 years were studied in an open-labeled single-arm conversion protocol. Twelve-hour pharmacokinetic studies were performed on Sandimmune and after 4 weeks of treatment with Neoral at similar dosage. The 24-hour blood pressure monitoring, creatinine clearance, and complete biochemistry profile were studied simultaneously to the pharmacokinetic studies. Six-month follow-up with serial measurements of cyclosporine levels, and biochemistry profile was completed.
Conversion to Neoral resulted in a 24% increase in area-under-the-curve in spite of no significant changes in cyclosporine trough levels (165 +/- 48 [Sandimmune] vs 169 +/- 32 nmol/L; p = 0.26). Respectively, 16%, 68%, and 16% were poor, average, and good absorbers on Sandimmune versus 26% and 74% being average or good absorbers on Neoral. Averaged systolic and diastolic blood pressure were not affected by Neoral, but blood pressure readings increased in 20% of patients previously known as having hypertension. The 24-hour blood pressure data yielded no significant changes with Neoral, but the nocturnal drop in systolic blood pressure was attenuated by Neoral. Twenty-four-hour creatinine clearance was not affected by Neoral, but serum magnesium levels decreased significantly at 6 months.
Neoral resulted in 24% increase in cyclosporine exposure without significant changes in trough levels, and improved absorption status. This greater drug exposure is well tolerated and resulted in a slight increase in blood pressure in a subset of patients and some decrease in magnesium levels, but it had no effect on renal function.
环孢素是一种强效免疫抑制剂,然而,它与系统性高血压和肾功能障碍有关。本研究的目的是比较山地明(山德士公司)和新山地明(诺华公司)两种环孢素制剂在心脏移植受者中的药代动力学以及长期肾脏和高血压效应。
采用开放标签单臂转换方案,对20例病情稳定、年龄为54±9岁的心脏移植受者进行研究。在相似剂量下,对山地明进行12小时药代动力学研究,并在使用新山地明治疗4周后重复该研究。在进行药代动力学研究的同时,同步进行24小时血压监测、肌酐清除率和全生化指标检测。完成6个月的随访,期间连续测定环孢素水平和生化指标。
转换为新山地明后,曲线下面积增加了24%,尽管环孢素谷浓度无显著变化(山地明组为165±48,新山地明组为169±32 nmol/L;p = 0.26)。在山地明组中,吸收不良、中等和良好的患者分别占16%、68%和16%,而在新山地明组中,中等或良好吸收者分别占26%和74%。新山地明对平均收缩压和舒张压无影响,但在既往有高血压的患者中,20%的患者血压读数升高。新山地明对24小时血压数据无显著影响,但可减弱夜间收缩压下降幅度。新山地明对24小时肌酐清除率无影响,但在6个月时血清镁水平显著降低。
新山地明使环孢素的暴露量增加24%,谷浓度无显著变化,并改善了吸收状态。这种更高的药物暴露耐受性良好,导致部分患者血压略有升高,镁水平有所降低,但对肾功能无影响。